Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes

Autor: Krishna Adeshara, Daniel Gordin, Anni A. Antikainen, Valma Harjutsalo, Niina Sandholm, Markku J. Lehto, Per-Henrik Groop, on behalf of the FinnDiane Study Group
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-9 (2024)
Druh dokumentu: article
ISSN: 1475-2840
DOI: 10.1186/s12933-024-02316-w
Popis: Abstract Background Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we investigated the association between serum protein glycation products and progression of kidney disease as well as incident major adverse cardiovascular events (MACE) in type 1 diabetes. Methods Fructosamine, advanced glycation end products (AGEs), and methylglyoxal-modified hydro-imidazolone (MG-H1) were measured from baseline serum samples in the FinnDiane study (n = 575). Kidney disease progression was defined as steep eGFR decline (> 3 mL/min/1.73 m2/year) or progression of albuminuria (from lower to higher stage of albuminuria). MACE was defined as acute myocardial infarction, coronary revascularization, cerebrovascular event (stroke), and cardiovascular death. Results Fructosamine was independently associated with steep eGFR decline (OR 2.15 [95% CI 1.16–4.01], p = 0.016) in the fully adjusted model (age, sex, baseline eGFR). AGEs were associated with steep eGFR decline (OR 1.58 per 1 unit of SD [95% CI 1.07–2.32], p = 0.02), progression to end-stage kidney disease (ESKD) (HR 2.09 per 1 unit of SD [95% CI 1.43–3.05], p
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje